Efficacy and Safety of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion Administered as Monotherapy in Patients with Parkinson's Disease

被引：0
|
作者：
Aldred, J.
Henriksen, T.
Bouchard, M.
Martinez-Castrillo, J.
Soileau, M.
Spiegel, A.
Bergmann, L.
Gupta, R.
Kukreja, P.
Standaert, D.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
19
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [41] Foslevodopa/Foscarbidopa in Patients with Advanced Parkinson's Disease: Subgroup Analyses from a Phase 3, Randomized Study
    Soileau, M.
    Fisseha, N.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Robieson, W.
    Talapala, S.
    Vaou, E.
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2023, 38 : S51 - S51
  • [42] Treatment Patterns with Long-Term Foslevodopa/Foscarbidopa Use in Parkinson's disease (PD)
    Aldred, J.
    Henriksen, T.
    Bouchard, M.
    Martinez-Castrillo, J.
    Soileau, M.
    Standaert, D.
    Bergmann, L.
    Gupta, R.
    Kukreja, P.
    Shah, M.
    Isaacson, S.
    MOVEMENT DISORDERS, 2024, 39 : S325 - S326
  • [43] Subcutaneous foslevodopa/foscarbidopa in patients with advanced Parkinson's Disease: results from a randomized, double-blind, double-dummy phase 3 trial
    Soileau, M.
    Spindler, M.
    Aldred, J.
    Budur, K.
    Fisseha, N.
    Fung, V.
    Jeong, A.
    Kimber, T.
    Klos, K.
    Litvan, I.
    O'Neill, D.
    Robieson, W.
    Standaert, D.
    Talapala, S.
    Vaou, E. Okeanis
    Zheng, H.
    Facheris, M.
    Hauser, R.
    MOVEMENT DISORDERS, 2022, 37 : S354 - S354
  • [44] Multicenter study of efficacy and safety of subcutaneous foslevodopa/foscarbidopa treatment initiation or switch from LD/CD intestinal gel
    Morales-Casado, M.
    Tabar-Comellas, G.
    Gisbert-Tijeras, E.
    Garcia-Melendez, D. D.
    Dominguez-Bertalo, J.
    Rivero-Rodriguez, D.
    Lopez-Ariztegui, N.
    MOVEMENT DISORDERS, 2024, 39 : S397 - S397
  • [45] Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson's Disease
    Fung, V.
    Aldred, J.
    Bergquist, F.
    Danielsen, E.
    Jeong, A.
    Jia, J.
    Spiegel, A.
    Talapala, S.
    Carroll, C.
    MOVEMENT DISORDERS, 2023, 38 : S23 - S24
  • [46] Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease
    Pfeiffer, Ronald F.
    Gutmann, Ludwig
    Hull, Keith L., Jr.
    Bottini, Peter B.
    Sherry, James H.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 (02) : 93 - 100
  • [47] Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease.
    Drapier, S.
    Verin, M.
    REVUE NEUROLOGIQUE, 2006, 162 (10) : 1019 - 1023
  • [48] Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease
    Moes, Harmen R.
    Buskens, Erik
    van Laar, Teus
    LANCET NEUROLOGY, 2024, 23 (09) : 856 - 857
  • [49] Continuous apomorphine infusion: Efficacy in patients with advanced Parkinson's disease (PD)
    Zamarbide, I
    Alonso, F
    Rodriguez-Oroz, MC
    Aristu, A
    Obeso, JA
    MOVEMENT DISORDERS, 2004, 19 : S254 - S254
  • [50] Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life with Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson's disease (PD): Interim Results From an Ongoing Open Label Extension
    Bergquist, F.
    Aldred, J.
    Carroll, C.
    Danielsen, E.
    Facheris, M.
    Gupta, R.
    Jeong, A.
    Spiegel, A.
    Fung, V.
    MOVEMENT DISORDERS, 2024, 39 : S322 - S323
12345